search
Back to results

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition

Primary Purpose

Type 2 Diabetes Mellitus

Status
Unknown status
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
CKD-387
D635
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

19 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy adults aged 19 to 55 years
  2. Females must be menopause or surgical infertility
  3. Signed informed consent form
  4. Other inclusion criteria, as defined in the protocol

Exclusion Criteria:

  1. History of clinically significant hepatic, renal, nervous, immune, respiratory, endocrine, hemato-oncology, cardiovascular systemic disease or psychosis disorder

  2. Clinical laboratory test values are outside the accepted normal range at Screening

    • aspartate aminotransferase(AST), alanine aminotransferase(ALT) > 1.25 times the upper limit of the normal range
    • Total Bilirubin > 1.5 times the upper limit of the normal range
    • creatine phosphokinase(CPK) > 1.5 times the upper limit of the normal range
    • estimated Glomerular Filtration Rate(eGFR, MDRD* formula) < 60 mL/min/1.73m2 (*MDRD: Modification of Diet in Renal Disease)
    • Positive reaction on following tests: Hepatitis B, Hepatitis C, human immunodeficiency virus(HIV) and syphilis
    • systolic blood pressure(SBP) ≥ 150 mmHg or < 90 mmHg, diastolic blood pressure(DBP) > 100 mmHg or < 50 mmHg
  3. Subject who smoke heavily or drink caffeine or alcohol continuously and who cannot discontinue smoking, caffeine or alcohol intake during hospitalization
  4. Participated in a clinical trial within 90 days prior to 1st IP dosing
  5. Not eligible to participate for the study at the discretion of Investigator
  6. Other exclusive inclusion criteria, as defined in the protocol

Sites / Locations

  • Severance Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Group 1

Group 2

Arm Description

Period 1: D635 Period 2: CKD-387

Period 1: CKD-387 Period 2: D635

Outcomes

Primary Outcome Measures

Cmax of Metformin
Maximum plasma concentration of Metformin
AUClast of Metformin
Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration

Secondary Outcome Measures

AUCinf of Metformin
Area under the plasma concentration of Metformin-time curve from time zero to infinity
Tmax of Metformin
Time to reach maximum (peak) plasma concentration of Metformin following drug administration
t1/2 of Metformin
Half-life of Metformin
CL/F of Metformin
Apparent clearance of Metformin
Vd/F of Metformin
Apparent volume of distribution of Metformin

Full Information

First Posted
February 20, 2019
Last Updated
February 20, 2019
Sponsor
Chong Kun Dang Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT03849339
Brief Title
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition
Official Title
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition in Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
January 28, 2019 (Actual)
Primary Completion Date
February 21, 2019 (Anticipated)
Study Completion Date
February 28, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the clinical trail is to evaluate the pharmacokinetics and safety/tolerability after oral administration of CKD-387 and D635 under fed condition in healthy adults.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1
Arm Type
Experimental
Arm Description
Period 1: D635 Period 2: CKD-387
Arm Title
Group 2
Arm Type
Experimental
Arm Description
Period 1: CKD-387 Period 2: D635
Intervention Type
Drug
Intervention Name(s)
CKD-387
Intervention Description
Test drug
Intervention Type
Drug
Intervention Name(s)
D635
Intervention Description
Reference drug
Primary Outcome Measure Information:
Title
Cmax of Metformin
Description
Maximum plasma concentration of Metformin
Time Frame
0 hour ~ 48 hour after drug administration
Title
AUClast of Metformin
Description
Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration
Time Frame
0 hour ~ 48 hour after drug administration
Secondary Outcome Measure Information:
Title
AUCinf of Metformin
Description
Area under the plasma concentration of Metformin-time curve from time zero to infinity
Time Frame
0 hour ~ 48 hour after drug administration
Title
Tmax of Metformin
Description
Time to reach maximum (peak) plasma concentration of Metformin following drug administration
Time Frame
0 hour ~ 48 hour after drug administration
Title
t1/2 of Metformin
Description
Half-life of Metformin
Time Frame
0 hour ~ 48 hour after drug administration
Title
CL/F of Metformin
Description
Apparent clearance of Metformin
Time Frame
0 hour ~ 48 hour after drug administration
Title
Vd/F of Metformin
Description
Apparent volume of distribution of Metformin
Time Frame
0 hour ~ 48 hour after drug administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy adults aged 19 to 55 years Females must be menopause or surgical infertility Signed informed consent form Other inclusion criteria, as defined in the protocol Exclusion Criteria: History of clinically significant hepatic, renal, nervous, immune, respiratory, endocrine, hemato-oncology, cardiovascular systemic disease or psychosis disorder Clinical laboratory test values are outside the accepted normal range at Screening aspartate aminotransferase(AST), alanine aminotransferase(ALT) > 1.25 times the upper limit of the normal range Total Bilirubin > 1.5 times the upper limit of the normal range creatine phosphokinase(CPK) > 1.5 times the upper limit of the normal range estimated Glomerular Filtration Rate(eGFR, MDRD* formula) < 60 mL/min/1.73m2 (*MDRD: Modification of Diet in Renal Disease) Positive reaction on following tests: Hepatitis B, Hepatitis C, human immunodeficiency virus(HIV) and syphilis systolic blood pressure(SBP) ≥ 150 mmHg or < 90 mmHg, diastolic blood pressure(DBP) > 100 mmHg or < 50 mmHg Subject who smoke heavily or drink caffeine or alcohol continuously and who cannot discontinue smoking, caffeine or alcohol intake during hospitalization Participated in a clinical trial within 90 days prior to 1st IP dosing Not eligible to participate for the study at the discretion of Investigator Other exclusive inclusion criteria, as defined in the protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Min Soo Park, Ph.D. M.D.
Organizational Affiliation
Severance Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Severance Hospital
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition

We'll reach out to this number within 24 hrs